Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Bio: Now Or Never. I Go With Never (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech punts near $300 million on Takeda discard
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
5 Best Biotech Stocks for 2018 | InvestorPlace
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Seen as Takeover Target After Strong Cancer Drug Data - TheStreet
Why Puma Biotech Could Get Acquired Between July to September of This Year | BioSpace
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Takeda farms out cancer drug alisertib to Puma Biotech | pharmaphorum
UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Opinion: 15 biotech stocks to put on your watch list now - MarketWatch
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
